The Strengthening Families Program for Youth 10-14 (SFP10-14), an evidence-based intervention that reduces teen substance use, also reduced participants’ friends’ substance use. Two factors that accounted for the nonparticipants’ reductions were less time spent by nonparticipants with their participating friends without adult supervision and improvements in nonparticipants’ attitudes toward substance use. The findings suggest that researchers should consider the potential for diffusion of benefits in designing and implementing prevention programs.
The finding from an 18-month-long clinical trial strengthens hope that pharmacotherapy can break nicotine’s especially tenacious hold on people with serious mental illness such as bipolar disorder or schizophrenia.
Despite common concerns that encouraging patients to quit smoking might endanger their success in treatment of substance use and mood or anxiety disorders, smoking cessation appears unlikely to hinder and may even help recovery.
One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.
Exposing rats to THC increases the likelihood that the animals will later self-administer nicotine. THC-exposed rats are also willing to work harder to obtain nicotine. When extrapolated to people, the findings suggest that THC’s pharmacological impact on the brain may make a person who uses marijuana more vulnerable to developing nicotine addiction, an underappreciated health consequence of marijuana use.
Teen mothers on three American Indian reservations improved on several measures of parenting after participating in Family Spirit, a home-visiting intervention developed with NIDA support. At 12 months postpartum, the women’s children exhibited reduced rates of emotional difficulties predicting later drug abuse and other behavioral problems. Infants at highest risk—those whose mothers had histories of drug abuse—benefited the most.
A meta-analysis of 13 genome-wide association studies of African Americans’ smoking patterns confirms the significance of genetic variation in region 15q25.1. The analysis also tentatively implicates several genome locations that have not previously been associated with smoking behaviors.
Women who reached their majority in states with policies that restricted teens’ access to tobacco products were less likely to smoke from ages 18-34 than women in states without those policies. The research did not demonstrate that the policies had a comparable impact on men’s smoking.
Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
Men benefit more than women from nicotine replacement therapy for smoking cessation because nicotine affects a key neuroreceptor differently in the two sexes, a NIDA-sponsored study suggests. The findings highlight the need for alternative therapies for women smokers, and point to the female hormone progesterone as a potential therapeutic target.
Fewer teens are using cigarettes, alcohol, and most illicit drugs, according to NIDA’s latest Monitoring the Future study. Troubling trends persist in marijuana use, however, and nonmedical prescription drug use remains a concern.
Nicotine sensitizes the mouse brain to the addictive effects of cocaine, according to recent NIDA-supported research. The results accord with the hypothesis that a person’s initial use of an addictive substance physiologically sensitizes his or her brain to the rewarding and addictive effects of other substances. If the findings carry over to people, then preventing youths from smoking might reduce their vulnerability to cocaine abuse and addiction, and cocaine-dependent individuals might ease their path to recovery by quitting smoking.
The immune system has an extraordinary ability to recognize compounds foreign to the body and eliminate them. NIDA-sponsored scientists are working to harness this ability to create vaccines that will protect individuals against the psychogenic and addictive effects of abused drugs. This animation shows one of the most promising strategies, which has already yielded partial success in producing effective vaccines against nicotine, cocaine, and other drugs.
The NIDA-supported Good Behavior Game recently was honored with the 2012 Mentor International Best Practice Award. The game, which focuses on reducing disruptive behaviors in elementary school classrooms, has been shown to prevent drug abuse and other problems in adolescence and young adulthood.
Towns that implemented a drug abuse prevention program called Communities That Care will see a return of $5.30 for each $1 they invested during the 5-year trial of the intervention, according to a cost-benefit analysis. The estimate is based on reductions in smoking and delinquency observed during the fourth year of the study among eighth-graders and the projected total costs of smoking, delinquency, and crime avoided over the lifetimes of study participants.
Illicit drug use in the United States in 2010 was at its highest level since 2002, according to the most recent report from the National Survey on Drug Use and Health. A rise in marijuana use drove the increase. A favorable trend of falling cocaine use continued.
Pregnant women who received financial incentives to refrain from smoking during late pregnancy were more successful at remaining abstinent and less likely to have babies with low birth weight, according to data from three trials.
While viewing images of cigarettes, smokers reported milder cravings when they shifted their focus from the pleasures of smoking to its harmful effects. Brain imaging showed a correlation between the reductions in craving and altered activity levels in regions associated with emotional regulation and reward.
Dr. Volkow discusses NIDA’s efforts to develop effective antismoking treatments for populations with persistently high rates of smoking, such as people with psychiatric disorders, high school dropouts, and Native Americans.
New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.
Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
Helping smokers deal with financial problems could improve their chances of staying abstinent after receiving treatment, according to a new study. Participants with the most financial strain had the least success in remaining abstinent.
Individuals with weak signaling in a nicotine-sensitive brain circuit were more vulnerable to nicotine dependence than those with stronger signaling, according to a study conducted while the subjects’ brains were in a resting state. A second resting-state study finds that the same circuit appears to mediate dependence associated with a genetic risk factor for smoking.
Examines results from a randomized clinical trial which found that treatment with a nicotine patch and nicotine lozenge together produced the greatest benefits in helping people quit smoking and remain abstinent.